Stocktoria
Avalo Therapeutics, Inc. AVTX
Avalo Therapeutics, Inc. (AVTX) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $59,000 at a -132642.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.793 |
| Retained earnings / assets | -3.851 |
| EBIT / assets | -0.626 |
| Equity / liabilities | 2.486 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | 1/9 | -8.95 | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
| INO | INOVIO PHARMACEUTICALS, INC. | — | — | — | — |
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
About Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
FAQ
Is AVTX financially healthy?
Avalo Therapeutics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does AVTX pay a dividend?
No, Avalo Therapeutics, Inc. does not currently pay a dividend.
How profitable is AVTX?
In FY2025, Avalo Therapeutics, Inc. had a net margin of -132642.4% and a return on equity of -94.2%.
What is the analyst price target for AVTX?
The average Wall-Street price target for Avalo Therapeutics, Inc. is $45.25, about 131.5% above the recent price, from 12 analysts (consensus: strong buy).
Is AVTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Avalo Therapeutics, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.